We can’t show the full text here under this license. Use the link below to read it at the source.
Effects of CT-388, a once-weekly signaling-biased dual GLP-1/GIP receptor agonist, on weight loss and glycemic control in preclinical models and participants with obesity
Weight loss and blood sugar control with once-weekly CT-388, a drug targeting two hormone receptors, in obesity studies and patients
AI simplified
Abstract
The mean percent change in bodyweight from baseline to day 29 was -4.7% to -8.0% across CT-388 doses compared to -0.5% with placebo.
- Biased activation of GLP-1R and GIPR by CT-388 resulted in minimal receptor internalization compared to native ligands.
- CT-388 improved glycemic control and reduced body weight in preclinical models, showing effects on appetite and metabolic dysfunction.
- In a phase 1 clinical trial, CT-388 was generally well tolerated, with most treatment-emergent adverse events being mild or moderate.
- Glycemic parameters improved during fasting and an oral glucose tolerance test after CT-388 treatment.
- Pharmacokinetic data indicated that CT-388 supports once-weekly dosing.
AI simplified